By Nono Hu, Marketing/PR Manager, LSN
 Life Science Nation (LSN), in collaboration with the UMASS Boston Venture Development Center (VDC), announces Life Science Fundraising Accelerator, a program designed to fill the void in the procurement of early stage life science capital. Currently, the scientist-entrepreneur struggles to go "the last three feet" and get in front of an investor, create a dialogue, build a relationship, and secure capital allocations...
|
|
 There's a lot going on in early stage venture-capital investment, and everyone is trying to follow the bouncing ball. In light of reports that venture-backed life science and biotech deals are off to their hottest start since 2007, LSN is pleased to announce the venture capital panel for the upcoming RESI Conference: Re-envisioning the Traditional Venture Model.
The panel will have representatives from some of the biggest global VC firms. Moderated by Bernadette Adamo of Silicon Valley Bank, the audience will hear from Kush Parmar, Partner at 5AM Ventures, Jayson Punwani, Partner at Pappas Ventures, Jerel Davis, Operating Partner at Versant Ventures, and Kiran Reddy, Associate Partner at Third Rock Ventures...
|
By Michael Quigley, Research Manager, LSN
 There is a common perception in the industry that direct medical-device investment has all but frozen over the past few years. As a fundraising entrepreneur, this is an easy kickstand to lean on when you have trouble securing financing for your proprietary technology. Data gathered over the past nine months by the research team here at LSN paints a different, much more positive picture, however. After reaching out to thousands of investors throughout the life science industry, we have identified and interviewed more than 300 qualified investors actively seeking to allocate to the medical device space.
Many may argue that 300 investors represent the marketplace as a whole, not the investors interested in early stage, higher-risk opportunities. However, the chart below shows the highest level of investor interest lies in the venture stage... READ MORE |
Life Science Investor Mandates
